Back to Search
Start Over
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.
- Source :
-
Oncogene . 10/22/2015, Vol. 34 Issue 43, p5411-5417. 7p. - Publication Year :
- 2015
-
Abstract
- Targeting a T-cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 09509232
- Volume :
- 34
- Issue :
- 43
- Database :
- Academic Search Index
- Journal :
- Oncogene
- Publication Type :
- Academic Journal
- Accession number :
- 110459437
- Full Text :
- https://doi.org/10.1038/onc.2015.5